The behaviour of GM130 in cancer is controversial, with studies indicating that it is either downregulated [e.g., in colorectal and breast cancers (Baschieri et al., 2014)] or upregulated [e.g., in gastric cancer, (Zhao et al., 2015); in lung cancer (Chang et al., 2012)] in certain cancer types. This evidence concerns the gene GOLGA2 and breast carcinoma.